Andrew Lugsdin - Information Technology Chair

Partner – IT Venture Fund

Andrew is a partner in the IT Venture Fund. He joined BDC Capital in 2001 and is based out of Vancouver, BC. He has over 20 years experience in the IT and telecom sectors.

Prior to joining BDC Capital, Andrew was the founder and president of a consulting firm for early-stage high-tech companies, providing business planning and development services. Previously, as Vice President of Sales and Client Strategy, he helped transform a Vancouver-based professional Web services firm into a Canadian leader. Andrew also worked for a number of years as a software engineer at Nortel and as a consultant for the DMR Group.


Andrew Haughian - Sustainable Technology Chair

General Partner

Andrew Haughian has over 15 years of energy and industrial experience. Andrew began his career in the upstream oil and gas industry before transitioning into engineering risk management consulting. He has a deep understanding of advanced materials commercialization and serves on the Editorial Board of the Journal, Translational Materials Research. Andrew serves on the board of CarbonCure Technologies, Energy Storage Systems Inc. and Tivra Corporation. He previously served on the boards of RSI Inc. and Boulder Ionics which were sold in 2014. Andrew holds a Bachelor of Applied Science (Mechanical Engineering) from the University of Toronto and a Masters in Business Administration degree from the Sauder School of Business at the University of British Columbia.

Mary Haak-Frendscho - Health Technology Chair


Mary Haak-Frendscho is CEO and member of the Board of Directors of Blueline Bioscience, and a Venture Partner with Versant Ventures. Dr. Haak-Frendscho also serves on the Board of Directors at Northern Biologics and as Executive Chair of Sirenas.

Mary brings 25 years of biotechnology industry experience spanning global pharma to early stage biotech start-ups. Prior to joining Blueline, she established and was Chairman of the Board of Compugen, Inc. and was CEO and member of the Board at Igenica Biotherapeutics, Inc. Previously Mary was founding President, CSO and Board member of Takeda San Francisco, establishing and overseeing Takeda’s Center of Excellence for Biologics. Earlier in her career Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led therapeutic programs. At Genentech, she played a key role in the development of omalizumab (Xolair®).